Supplementary Figure S2 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study | Synapse
September 16, 2025
Supplementary Figure S2 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Key Points
The analysis includes samples from baseline and on-treatment periods in different treatment arms, indicating comprehensive data collection.
One patient in arm 2A and three patients in arm 2B did not undergo cystectomy, impacting treatment assessment.
The focus is on biomarker dynamics related to ipilimumab and nivolumab in locally advanced urothelial cancer.
The phase IB NABUCCO study highlights the interaction between treatment and biomarker changes.
Abstract
Consort diagram of available samples per analysis for each arm at baseline and on-treatment. One patient in arm 2A and 3 patients in arm 2B did not undergo cystectomy.